(3R)-3-Benzyloxycarbonyl-3-phenylmethylpropionic acid | 116129-80-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3R)-3-Benzyloxycarbonyl-3-phenylmethylpropionic acid
• 英文别名: benzyl (2R)-2-(carboxymethyl)-3-phenylpropionate；benzyl (2R)-2-(carboxymethyl)-3-phenyl-propionate；2R-benzyl butanedioic acid, 1-benzyl ester；benzyl (2R)-3-Carboxy-2-benzylpropionate；2R-(Phenylmethyl)butanedioic acid, 1-(phenylmethyl) ester；(R)-2-Benzyl-succinic acid 1-benzyl ester；(3R)-3-benzyl-4-oxo-4-phenylmethoxybutanoic acid
• CAS: 116129-80-7
• 化学式: C₁₈H₁₈O₄
• 分子量: 298.339
• InChiKey: ZXEOHROMGBZHPE-MRXNPFEDSA-N

物化性质

• 沸点：
  467.9±33.0 °C(Predicted)
• 密度：
  1.205±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3R)-3-Benzyloxycarbonyl-3-phenylmethylpropionic acid 在 palladium on activated charcoal N-乙基吗啉 、 草酰氯 、 氢气 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 苯硫酚 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 12.5h， 生成 N--(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6(2-pyridyl)-hexane-2-amide acetate
  参考文献：
  名称：

  肾素抑制剂，其包含吡啶基氨基二醇衍生的C端。

  摘要：

  基于过渡态类似物的概念，一系列具有新的（2S，3R，4S）-2-氨基-1-环己基-3,4-二羟基-6-（2-吡啶基）己烷部分的非肽肾素抑制剂合成了在C-末端的C末端功能，并在体外和体内评估了对肾素的抑制。当与人肾素进行体外测试时，所有化合物均显示出纳摩尔或什至亚纳摩尔范围的效力。在麻醉的，钠缺乏的恒河猴中评估选定的抑制剂，并在十二指肠内给予2 mg / kg的剂量后，平均动脉血压（MAP）明显降低。含有氨基哌啶基琥珀酸衍生的N端的化合物38（S 2864）是该系列中最有希望的成员。38种抑制人肾素的IC50为0.38 nM，不影响其他人天冬氨酸蛋白酶，

  DOI：

  10.1021/jm00071a009
• 作为产物：
  描述：

  (S)-4-苄基-3-(3-苯基丙酰基)噁唑烷丁-2-酮 在 正丁基锂 、 sodium hexamethyldisilazane 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 6.75h， 生成 (3R)-3-Benzyloxycarbonyl-3-phenylmethylpropionic acid
  参考文献：
  名称：

  肾素抑制剂，其包含吡啶基氨基二醇衍生的C端。

  摘要：

  基于过渡态类似物的概念，一系列具有新的（2S，3R，4S）-2-氨基-1-环己基-3,4-二羟基-6-（2-吡啶基）己烷部分的非肽肾素抑制剂合成了在C-末端的C末端功能，并在体外和体内评估了对肾素的抑制。当与人肾素进行体外测试时，所有化合物均显示出纳摩尔或什至亚纳摩尔范围的效力。在麻醉的，钠缺乏的恒河猴中评估选定的抑制剂，并在十二指肠内给予2 mg / kg的剂量后，平均动脉血压（MAP）明显降低。含有氨基哌啶基琥珀酸衍生的N端的化合物38（S 2864）是该系列中最有希望的成员。38种抑制人肾素的IC50为0.38 nM，不影响其他人天冬氨酸蛋白酶，

  DOI：

  10.1021/jm00071a009

文献信息

• Propargyl glycine amino use of propargyl diol compounds for treatment of
  申请人：G.D. Searle & Co.

  公开号：US05484812A1

  公开（公告）日：1996-01-16

  Compounds characterized generally as propargyl glycine amino propargyl diol derivatives are useful as renin inhibitors for the treatment of ophthalmic disorders. Compounds of particular interest are those of Formula I ##STR1## wherein A is selected from CO and SO.sub.2 wherein X is selected from oxygen atom and methylene; wherein each of R.sub.1 and R.sub.9 is a group independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, benzyl, b, b, b-trifluoroethyl, t-butyloxycarbonyl and methoxymethylcarbonyl, and wherein the nitrogen atom to which R.sub.1 and R.sub.9 are attached may be combined with oxygen to form an N-oxide; wherein R.sub.2 is selected from hydrido, methyl, ethyl and isopropyl; wherein R.sub.3 is selected from benzyl, cyclohexylmethyl, phenethyl, imidazolemethyl, pyridylmethyl and 2-pyridylethyl; wherein R.sub.5 is propargyl or a propargyl-containing moiety; wherein R.sub.7 is cyclohexylmethyl; wherein each of R.sub.4 and R.sub.6 is independently selected from hydrido and methyl; wherein R.sub.8 is selected from ethyl, n-propyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclohexylmethyl, cyclohexylethyl, allyl, vinyl and fluorovinyl; wherein each of R.sub.11 and R.sub.12 is independently selected from hydrido, alkyl and phenyl; wherein m is zero; and wherein n is a number selected from zero through three; or a pharmaceutically-acceptable salt thereof.

  一般被表征为丙炔基甘氨酸氨基丙炔基二醇衍生物的化合物，可用作治疗眼科疾病的肾素抑制剂。特别感兴趣的化合物是公式I所示的那些##STR1##，其中A选自CO和SO.sub.2，X选自氧原子和亚甲基；其中R.sub.1和R.sub.9各自独立地选自氢、甲基、乙基、正丙基、异丙基、苄基、b, b, b-三氟乙基、t-丁氧羰基和甲氧基甲氧基羰基，并且R.sub.1和R.sub.9所连接的氮原子可以与氧结合形成一个N-氧化物；其中R.sub.2选自氢、甲基、乙基和异丙基；其中R.sub.3选自苄基、环己基甲基、苯乙基、咪唑烷基甲基、吡啶基甲基和2-吡啶基乙基；其中R.sub.5是丙炔基或含丙炔基的基团；其中R.sub.7是环己基甲基；其中R.sub.4和R.sub.6各自独立地选自氢和甲基；其中R.sub.8选自乙基、正丙基、异丁基、环丙基、环丁基、环戊基、环己基、环丙基甲基、环己基甲基、环己基乙基、烯丙基、乙烯基和氟乙烯基；其中R.sub.11和R.sub.12各自独立地选自氢、烷基和苯基；其中m为零；并且n是从零到三的数字；或其药物可接受的盐。
• Use of propargyl glycine amino propargyl diol compounds for inhibiting plasma renin activity
  申请人：G. D. Searle & Co.

  公开号：US06342624B1

  公开（公告）日：2002-01-29

  Compounds characterized generally as propargyl glycine amino propargyl diol derivatives are useful for treatment of a disorder mediated by inhibiting plasma renin activity. Compounds of particular interest are those of Formula I wherein A is selected from CO and SO2 wherein X is is selected from oxygen atom and methylene; wherein each of R1 and R9 is a group independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, benzyl, b, b, b-trifluoroethyl, t-butyloxycarbonyl and methoxymethylcarbonyl, and wherein the nitrogen atom to which R1 and R9 are attached may be combined with oxygen to form an N-oxide; wherein R2 is selected from hydrido, methyl, ethyl and isopropyl; wherein R3 is selected from benzyl, cyclohexylmethyl, phenethyl, imidazolemethyl, pyridylmethyl and 2-pyridylethyl; wherein each of R5 and R8 is independently propargyl or a propargyl-containing moiety; wherein R7 is cyclohexylmethyl; wherein each of R4 and R6 is independently selected from hydrido and methyl; wherein each of R11 and R12 is independently selected from hydrido, alkyl and phenyl; wherein m is zero; and wherein n is a number selected from zero through three; or a pharmaceutically-acceptable salt thereof.

  通常被描述为丙炔基甘氨酸氨基丙炔二醇衍生物的化合物，可用于治疗通过抑制血浆肾素活性介导的疾病。特别感兴趣的化合物是符合以下式I的化合物 其中A从CO和SO2中选择，X从氧原子和亚甲基中选择；R1和R9中的每一个独立选择自氢、甲基、乙基、正丙基、异丙基、苄基、三氟乙基、叔丁氧羰基和甲氧甲基羰基的基团，R1和R9附着的氮原子可以与氧结合形成N-氧化物；R2从氢、甲基、乙基和异丙基中选择；R3从苄基、环己基甲基、苯乙基、咪唑基甲基、吡啶基甲基和2-吡啶基乙基中选择；R5和R8中的每一个独立地是丙炔基或含丙炔基的基团；R7是环己基甲基；R4和R6中的每一个独立选择自氢和甲基；R11和R12中的每一个独立选择自氢、烷基和苯基；m为零；n为从零到三中选择的数字；或其药用可接受盐。
• Renin-inhibiting functionalized peptidyl aminodiols and - triols
  申请人：ABBOTT LABORATORIES

  公开号：EP0341602A2

  公开（公告）日：1989-11-15

  A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.

  一个公式为的抑制肾素的化合物： 或其药用可接受的盐、酯或前药。
• Heterocyclic peptide renin inhibitors
  申请人：Abbott Laboratories

  公开号：US05164388A1

  公开（公告）日：1992-11-17

  A renin inhibiting compound of the formula ##STR1## wherein X is N, O or CH; R.sub.1 is absent or a functional group; A and L are independently selected from absent, C.dbd.O, SO.sub.2 and CH.sub.2 ; D is C.dbd.O, SO.sub.2 or CH.sub.2 ; Y is N or CH; R.sub.2 is hydrogen, loweralkyl or substituted alkyl; Z is a functional group; R.sub.3 is loweralkyl or substituted alkyl; n is 0 or 1; and T is a mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

  公式##STR1##中的一种抑制肾素的化合物，其中X为N、O或CH；R.sub.1为空缺或为一个官能团；A和L分别从空缺、C.dbd.O、SO.sub.2和CH.sub.2中独立选择；D为C.dbd.O、SO.sub.2或CH.sub.2；Y为N或CH；R.sub.2为氢、较低烷基或取代烷基；Z为一个官能团；R.sub.3为较低烷基或取代烷基；n为0或1；T为血管紧张素原Leu-Val裂解位点的模拟物；或其药学上可接受的盐、酯或前药。
• Angiotensinogen analogs
  申请人：Abbott Laboratories

  公开号：US04857507A1

  公开（公告）日：1989-08-15

  The invention relates to renin inhibiting compounds of the formula ##STR1## wherein A is hydrogen; loweralkyl; arylalkyl; OR.sub.10 or SR.sub.10 wherein R.sub.10 is hydrogen, loweralkyl or aminoalkyl; NR.sub.11 R.sub.12 wherein R.sub.11 and R.sub.12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; ##STR2## wherein B is NH, alkylamino, S, O, CH.sub.2 or CHOH and R.sub.13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH.sub.2 or NR.sub.2 with the proviso that when W is CHOH then U is CH.sub.2 ; R.sub.1 is loweralkyl, cycloaklylmethyl, benzyl, .alpha.,.alpha.-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R.sub.1 is phenoxy, thiophenoxy or anilino, B is CH.sub.2 or CHOH or A is hydrogen, R.sub.3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R.sub.5 is loweralkyl, cycloalkylmethyl or benzyl; R.sub.2 and R.sub.4 are independently selected from hydrogen and loweralkyl; R.sub.6 is CHOH or CO; R.sub.7 is CH.sub.2, CF.sub.2 or CF with the proviso that when R.sub.6 is CO, R.sub.7 is CF.sub.2 ; R.sub.8 is CH.sub.2, CHR.sub.14 wherein R.sub.14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R.sub.7 and R.sub.8 taken together can be ##STR3## with the proviso that when R.sub.7 is CF.sub.2, R.sub.8 is CH.sub.2 ; E is O, S, SO, SO.sub.2, NR.sub.15 wherein R.sub.15 is hydrogen or loweralkyl or NR.sub.16 CO wherein R.sub.16 is hydrogen or loweralkyl; R.sub.9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R.sub.9 taken together can be N.sub.3, with the proviso that when E is NH, R.sub.9 is an N-protecting group; and pharmaceutically acceptable salts thereof.

  该发明涉及以下结构的肾素抑制化合物##STR1##其中A为氢；较低烷基；芳基烷基；OR.sub.10或SR.sub.10，其中R.sub.10为氢，较低烷基或氨基烷基；NR.sub.11 R.sub.12，其中R.sub.11和R.sub.12分别选择自氢，较低烷基，氨基烷基，氰基烷基和羟基烷基；##STR2##其中B为NH，烷基氨基，S，O，CH.sub.2或CHOH，R.sub.13为较低烷基，环烷基，芳基，芳基烷基，烷氧基，烯基氧基，羟基烷氧基，二羟基烷氧基，芳基烷氧基，芳基烷氧基烷基，氨基，烷基氨基，二烷基氨基，(羟基烷基)(烷基)氨基，(二羟基烷基)(烷基)氨基，氨基烷基，烷氧羰基烷基，羧基烷基，N-保护氨基烷基，烷基氨基烷基，(N-保护)(烷基)氨基烷基，二烷基氨基烷基，(杂环)烷基或取代或未取代的杂环；W为CO或CHOH，U为CH.sub.2或NR.sub.2，但当W为CHOH时，U为CH.sub.2；R.sub.1为较低烷基，环烷基甲基，苄基，.alpha.，.alpha.-二甲基苄基，4-甲氧基苄基，卤代苄基，(1-萘基)甲基，(2-萘基)甲基，(4-咪唑基)-甲基，苯乙基，苯氧基，噻吩氧基或苯胺基；但如果R.sub.1为苯氧基，噻吩氧基或苯胺基，B为CH.sub.2或CHOH或A为氢，R.sub.3为较低烷基，烯基较低烷基，苄基或杂环环取代甲基，R.sub.5为较低烷基，环烷基甲基或苄基；R.sub.2和R.sub.4分别选择自氢和较低烷基；R.sub.6为CHOH或CO；R.sub.7为CH.sub.2，CF.sub.2或CF，但当R.sub.6为CO时，R.sub.7为CF.sub.2；R.sub.8为CH.sub.2，CHR.sub.14，其中R.sub.14为较低烷基，环烷基，环烷基烷基，芳基或芳基烷基，或R.sub.7和R.sub.8一起可以是##STR3##但当R.sub.7为CF.sub.2时，R.sub.8为CH.sub.2；E为O，S，SO，SO.sub.2，NR.sub.15，其中R.sub.15为氢或较低烷基或NR.sub.16 CO，其中R.sub.16为氢或较低烷基；R.sub.9为较低烷基，环烷基，环烷基烷基，芳基，芳基烷基或N-保护基，或E和R.sub.9一起可以是N.sub.3，但当E为NH时，R.sub.9为N-保护基；及其药学上可接受的盐。